Sickle Cell Anemia

Introduction

Sickle-cell anemia is an inherited autosomal (“non-sex” chromosomes) recessive blood disease that affects millions of people throughout the world. It is caused by a mutation in the gene for beta hemoglobin (an oxygen-carrying molecule), producing a change in the shape of the red blood cell into a sickle shape (Ronald and Sandra, pp. 8-89). The distorted shape of the red blood cell is unable to pass through capillaries and causes blood clots to form. Consequently, these blockages impede the flow of blood, causing hemorrhaging as red blood cells (RBCs) enter surrounding tissue, giving rise to many complications throughout the body. This paper discusses sickle cell anemia in a concise and comprehensive way.

Sickle Cell Anemia: A Discussion

The disease was first discovered in Chicago in 1910 by James B. Herrick, who described the anemia as “peculiar elongated sickle-shaped” red blood cells in a young black student from the West Indies. Many scholars acknowledge that even before Herrick, the awareness of African cultures with the disease was characterized by the intense and chronic pain of the disease. This explains the early name “Chwechweechwe” given to the disease, which was a description of the recurring pain experienced by the patient.

Physical anthropologists of antiquity used “racial admixture” and “Negro blood” to imply that there was an inherent difference between the black and white races. However, with time, as physicians continued to discover sickle-shaped cells in “white” individuals in different areas of the world, the focus on sickle-cell anemia as purely a racial disease was challenged. Numerous cases of sickled cells were soon discovered in “white” populations throughout the Mediterranean, Mexico, and Europe.

The sickle-cell disease affects millions of people all across the globe. In the United States, approximately 72,000 people are affected by the disease, with the disease occurring in 1 in 500 African American births and 1 in 1000-1400 Hispanic American births. There are approximately 2 million Americans and 1 in 12 African Americans who are carriers of the sickle-cell trait. In Africa, there is a large variance throughout, with 40% of some tribes having the disease (Ronald and Sandra, pp. 8-89).

It was in 1949 that physical chemist Linus Pauling found that the sickle-cell disease was due to a molecular defect in the hemoglobin molecule. It was a specific point in the molecular composition of hemoglobin that Pauling suggested caused the sickling of red blood corpuscles. Molecular biologists determined that this disease was caused by an error in the amino acid substitution on hemoglobin. This was thought to be the first discovered molecular disease.

Molecular biology shows the importance of amino acid sequences during the formation of proteins. Each altered gene, called an allele, codes for different chemical and bonding interactions during protein formation. An individual who is homozygous for a gene has acquired two copies of one allele, SS (sickle-cell anemia) or AA (normal genotype) (Keith, pp. 111-119). If only one sickle allele is inherited, then he or she is heterozygous (AS). In order for someone to have the sickle-cell disease, he or she ...